APA (7th ed.) Citation

VM, N., Y, H., W, S., DN, E., & J, C. (2025). Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis. Cancer gene therapy, 32(8), 899. https://doi.org/10.1038/s41417-025-00934-4

Chicago Style (17th ed.) Citation

VM, Ngwa, Hwang Y, Song W, Edwards DN, and Chen J. "Targeting MTORC2 in Lung Squamous Cell Carcinoma Improves Anti-tumor Immunity Through the PSGL-1-VISTA Axis." Cancer Gene Therapy 32, no. 8 (2025): 899. https://doi.org/10.1038/s41417-025-00934-4.

MLA (9th ed.) Citation

VM, Ngwa, et al. "Targeting MTORC2 in Lung Squamous Cell Carcinoma Improves Anti-tumor Immunity Through the PSGL-1-VISTA Axis." Cancer Gene Therapy, vol. 32, no. 8, 2025, p. 899, https://doi.org/10.1038/s41417-025-00934-4.